Sign in
OYST Stock Price, Chart, Stats & News
Oyster Point Pharma, Inc.
Save
–
Market cap
–
Current P/E
–
Forward P/E
OYST chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.79% |
Operating margin | -394.98% |
Pretax margin | -410.20% |
Net margin | -425.42% |
Effective tax rate | -3.71% |
ROA | -46.89% |
ROE | -72.95% |
D/E | 0.93x |
Interest coverage ratio | -25.96x |
OYST valuation
P/E | – |
P/S | – |
P/B | 2.92x |
P/CF | -3.25x |
P/FCF | – |
P/OCF | -3.25x |
PEG | -0.03x |
EV multiple | -1.04x |
About
Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease.
Similar securities
Based on sector and market capitalization
Report issue